Teoxane to Present How MLT 3.1 Adresses Rapid Weight-Loss-Induced Facial Changes – A Multi-Layer, Holistic Approach Protocol for Facial Support, Volume Restoration and Skin Quality – at AMWC 2026 

A new clinical framework addressing the facial impact of rapid metabolic transformation induced by incretin-based therapies will be introduced through a scientific symposium and educational sessions, positioning MLT 3.1 as an integrated response to structure, volume and skin quality¹.

Two scientific posters will be presented and one of them as well as a dedicated symposium will introduce how Teoxane’s MLT 3.1 holistic technique addresses a full response to rapid weight loss. 

Geneva, Switzerland – March 2026 - At AMWC 2026, Teoxane will present MLT 3.1 (Multi-Layering Technique 3.1), a comprehensive, anatomy-based approach developed to address the facial consequences of rapid weight loss in the emerging metabolic era. As incretin-based therapies accelerate global weight reduction, facial tissues undergo profound structural and dermal changes requiring a new aesthetic strategy grounded in anatomical precision and tissue physiology².

MLT 3.1 reflects Teoxane’s technique-driven and education-led philosophy: moving from isolated corrections toward coordinated, multi-layer facial optimisation.

Scientific rationale Supporting MLT 3.1: Evidence from Two Clinical Contexts.

Teoxane’s scientific presence at AMWC 2026 will include two scientific posters exploring two distinct but mechanistically related clinical situations of medically driven facial volume loss: facial lipoatrophy associated with antiretroviral treatment3 , and rapid weight-loss–induced facial changes linked to incretin-based therapies⁴. Together, they provide complementary evidence supporting the relevance that Teoxane portfolio can support a balanced redistribution and skin quality approach in those specific contexts^3,4.  

One poster evaluates the use of resilient hyaluronic acid (HA) fillers in HIV associated facial lipoatrophy, demonstrating sustained volume restoration and facial harmony, high patient satisfaction and improved quality of life aspects, thus supporting the rational extension of this approach to other medically induced volume deficits³.  

The second poster focuses on patients experiencing rapid weight loss associated with Incretin mimetics (GLP-1 Receptor Agonists, GLP-1 RA), where drastic superficial fat compartment reduction, particularly in the tear trough, temples and midface, leads to significant volume loss, skin laxity and deterioration of skin quality, distinct from age-related facial ageing. Clinician-led case data presented in this work show that treatment with highly versatile HA fillers resulted in visible natural restoration of facial volume and contour, improvement in skin laxity and quality, and high levels of patient satisfaction, highlighting the benefit of such holistic treatment plan.  

Together, these findings highlight the need for an integrated, anatomy-driven strategy addressing both structural and dermal alterations. By combining deep structural support, targeted volumetric restoration and dermal optimisation within a single, coordinated framework, MLT 3.1 emerges as a clinically relevant and holistic response to medically and metabolically induced facial changes, supporting natural, harmonious outcomes while preserving facial identity^3,4.

Metabolic Transformation and The Facial Integrity: Understanding The New Aesthetic Reality

We are entering the metabolic era, where incretin-based therapies are accelerating weight loss globally². Bodies are transforming faster than ever.

Rapid weight loss induces measurable anatomical modifications affecting multiple facial layers: reduction of superficial and deep fat compartments, reduced structural support and projection, skin laxity from diminished underlying volume, altered hydration balance and dermal density².

While patients anticipate body transformation, they often do not anticipate accelerated facial ageing. Volume loss increases shadowing; dermal compromise contributes to dullness, laxity and fatigue appearance².

Treating volume alone leaves the dermis untreated. Treating surface alone ignores structural and volume decline.

MLT 3.1 was developed to address this layered disruption through a coordinated structural, volumetric and dermal approach delivered within a single, coherent protocol¹.

Multi-Layering Technique (MLT): Enhancing Facial Structure, Volume and Skin Quality

First introduced in 2019, the Multi-Layering Technique (MLT) is grounded in Teoxane’s ATP approach (Anatomy–Technique–Product), which aligns detailed anatomical assessment with precise injection strategy and tailored product selection⁵.

MLT was initially developed as a sequential, dual-layer injection protocol: an initial placement in deeper anatomical planes to reinforce structural support and projection, followed by the injection in superficial planes of a second hyaluronic acid formulation with dynamic properties to preserve facial movement, suppleness and expressiveness⁵.

This coordinated layering strategy optimises product efficiency while maintaining natural facial biomechanics⁶.

As clinical practice evolved and patient expectations shifted toward more comprehensive outcomes, the protocol expanded. In 2023, MLT evolved into MLT 3.1, formally introducing a third treatment dimension dedicated to skin quality, positioning dermal enhancement as an integral component of facial rejuvenation rather than an adjunct procedure⁷.

In 2024, this skin quality dimension was further structured through the launch of Teoxane babyGLOW^TM, a dedicated skin-quality protocol designed to be integrated as the “.1” component within the MLT 3.1 framework⁸.  

This addition expanded the paradigm from structural and volumetric correction toward full multi-layer optimisation and holistic approach.

At AMWC 2026, Teoxane will demonstrate how this established multi-layer framework provides a clinically relevant response to a rapidly emerging global phenomenon: the facial anatomical and dermal changes associated with accelerated weight loss.

Importantly, MLT 3.1 integrates skin quality as a fundamental component. Weight loss does not merely stretch the skin differently — it alters hydration balance, surface luminosity, texture, and elasticity². By combining volume and structure restoration with skin quality enhancement, MLT 3.1 hydrates, densifies, and brightens the skin while refining texture and supporting elasticity over time⁴. 
This personalized, multi-layered innovative approach allows a natural, and harmonious appearance⁵.  

Beyond in-clinic treatment, the integration of Teoxane Aesthetic Skincare ensures ongoing maintenance, turning a single session into a continuous journey of facial support and rejuvenation.

Teoxane Scientific Programming and Expert Education at AMWC 2026  

Teoxane’s scientific contribution will be further highlighted during the Teoxane Symposium, taking place on Thursday March 25th, from 14:00 to 16:00 at Prince Pierre Auditorium.

Lecture: Understanding Facial Changes. Patient Expectations and Aesthetic Trends, by Dr Sabrina Shah-Desai

Anatomy Lecture by Dr. Gisella Criollo Lamilla

Live injection: Gen Z Full Face Beautification held by Dr. Nabila Azib  

Case Study: Millennial Full-Face Rejuvenation, Male vs Female by Dr. Navid Alizadeh

Live injection: Perimenopausal Full Face Restauration held by Dr. Paula Rosso

Presented by Dr. Lee Walker (UK).  

"My scientific background is rooted in metabolic research, where I worked on glucose regulation mechanisms, including glucagon and incretin biology, within a preclinical and translational framework. The current expansion of incretin-based weight-loss therapies represents more than a metabolic shift; it is generating downstream implications for aesthetic medicine.

The rapid expansion of weight-loss therapies has created a new aesthetic phenotype – one characterized by volume shifts, skin quality changes, and altered facial dynamics. Neither patients nor practitioners were fully prepared for this acceleration.

Our role is to define clear frameworks and practical guidance that support clinicians in managing facial changes associated with rapid weight loss, ensuring safety, predictability, and long-term patient satisfaction” 

- Dr Mounia Heddad-Masson, PhD, Director Global Medical Education & Medical Affairs at Teoxane.